Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined. METHODS: We randomly assigned 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors to receive either lorcaserin (10 mg twice daily) or placebo. The primary safety outcome of major cardiovascular events (a composite of cardiovascular death, myocardial infarction, or stroke) was assessed at an interim analysis to exclude a noninferiority boundary of 1.4. If noninferiority was met, the primary cardiovascular efficacy outcome (a composite of major cardiovascular events, heart failure, hospitalization for unstable angina, or coronary revascularization [extended major cardiovascular events]) was assessed for superiority at the end of the trial. RESULTS: At 1 year, weight loss of at least 5% had occurred in 1986 of 5135 patients (38.7%) in the lorcaserin group and in 883 of 5083 (17.4%) in the placebo group (odds ratio, 3.01; 95% confidence interval [CI], 2.74 to 3.30; P<0.001). Patients in the lorcaserin group had slightly better values with respect to cardiac risk factors (including blood pressure, heart rate, glycemic control, and lipids) than those in the placebo group. During a median follow-up of 3.3 years, the rate of the primary safety outcome was 2.0% per year in the lorcaserin group and 2.1% per year in the placebo group (hazard ratio, 0.99; 95% CI, 0.85 to 1.14; P<0.001 for noninferiority); the rate of extended major cardiovascular events was 4.1% per year and 4.2% per year, respectively (hazard ratio, 0.97; 95% CI, 0.87 to 1.07; P=0.55). Adverse events of special interest were uncommon, and the rates were generally similar in the two groups, except for a higher number of patients with serious hypoglycemia in the lorcaserin group (13 vs. 4, P=0.04). CONCLUSIONS: In a high-risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo. (Funded by Eisai; CAMELLIA-TIMI 61 ClinicalTrials.gov number, NCT02019264 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [12]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [8]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [8]
In the citing paper
“lorcaserin, which had a neutral effect on MACEs in the CAMELLIA-TIMI 61 study”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [173]
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Flegal, K. M., Kit, B. K., Orpana, H., & Graubard, B. I. (2013) · JAMA · doi:10.1001/jama.2012.113905 · Cited by 3,998
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Hales, C. M., Fryar, C. D., Carroll, M. D., Freedman, D. S., & Ogden, C. L. (2018) · JAMA · doi:10.1001/jama.2018.3060 · Cited by 1,761
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Cited by
Items 101–200 of 267
Owaki, T., Kamimura, K., Ko, M., Nagayama, I., Nagoya, T., Shibata, O., Oda, C., Morita, S., Kimura, A., Sato, T., et al. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049612 · Cited by 19
“…neural pathways, including NPY/AgRP and POMC, and employing a HTR2C agonist approved by the U.S. Food and Drug Administration for BW management (Bohula et al., 2018a,b) should be conducted to clarify the contribution of appetite control and the relationship between the central and peripheral…”
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 22
Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2209176 · Cited by 19
Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice
Song, J.-E., Ko, H., & Kim, A. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s445415 · Cited by 25
Attitudes and perceptions of the general public on obesity and its treatment options in Singapore
Lee, P. C., Ganguly, S., Tan, H. C., Lim, C. H., Chan, W. H., Kovalik, J.-P., Eng, A., Tan, J., Lim, E., Chua, J., et al. (2019) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2019.03.007 · Cited by 18
A review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 21
Stahel, P., Lee, S. J., Sud, S. K., Floh, A., & Dash, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13661 · Cited by 18
Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
Do, A., Kuszewski, E. J., Langberg, K. A., & Mehal, W. Z. (2019) · Hepatology · doi:10.1002/hep.30658 · Cited by 20
“(21) Despite previous concerns of serotonin 5-HT2Bmediated cardiac valvulopathy, a large study of 12,000 patients with atherosclerotic disease or multiple cardiovascular risk factors showed no increased risk of cardiovascular disease within 1 year of lorcaserin initiation.(22) This medication is dosed 20 mg per day.”
BackgroundWaiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern
Hernández, D., Alonso-Titos, J., Armas-Padrón, A. M., López, V., Cabello, M., Sola, E., Fuentes, L., Gutiérrez, E., Vázquez, T., Jiménez, T., et al. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000504546 · Cited by 19
Suresh, K., Holtrop, J. S., Dickinson, L. M., Willems, E., Smith, P. C., Gritz, R. M., & Perreault, L. (2022) · Trials · doi:10.1186/s13063-021-05954-7 · Cited by 17
Capristo, E., Maione, A., Lucisano, G., Russo, M. F., Mingrone, G., & Nicolucci, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.023 · Cited by 18
Metformin: Expanding the Scope of Application—Starting Earlier than Yesterday, Canceling Later
Kononova, Y. A., Likhonosov, N. P., & Babenko, A. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042363 · Cited by 18
Sex Differences in Obesity and Its Treatment
Ghanta, A., Wilson, E., & Chao, A. M. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01601-z · Cited by 20
“Lorcaserin was voluntarily withdrawn from the US market in 2020 because of concerns of increased occurrence of cancer [ 65 ].”
Recent Advances in Anti-Obesity Agents
Kim, M. K., & Kim, C. S. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.6.501 · Cited by 16
Evidence-Based Cardiovascular Risk Management in Diabetes
Mooradian, A. D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00336-6 · Cited by 16
Pharmacophore Directed Screening of Agonistic Natural Molecules Showing Affinity to 5HT2C Receptor
Veeramachaneni, G. K., Thunuguntla, V. B. S. C., Bhaswant, M., Mathai, M. L., & Bondili, J. S. (2019) · Biomolecules · doi:10.3390/biom9100556 · Cited by 16
“Many side effects like cardiovascular problems, nausea, vomiting, constipation, diarrhea, fatigue, upper respiratory tract infection, urinary tract infections, back pain, headache, dizziness and rash were reported by Lorcaserin usage [25,26].”
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg, D. D., Moura, F. A., Bellavia, A., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Raz, I., Bohula, E. A., Giugliano, R. P., Park, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.031 · Cited by 14
Self-citationMoura, F. A., Berg, D. D., Bellavia, A., Dwyer, J. P., Mosenzon, O., Scirica, B. M., Wiviott, S. D., Bhatt, D. L., Raz, I., Feinberg, M. W., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0492 · Cited by 16
Self-citationDrug-drug interactions when treating HIV-related metabolic disorders
Gutiérrez, M. D. M., Mateo, G. M., Corbacho, N., Vidal, F., & Domingo, P. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1667334 · Cited by 14
The 5-HT-related gut-brain axis in obesity
Jiang, C., Zhan, Q., & Zeng, C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123171 · Cited by 14
Giovanni, C. B. S., Sweeney, B. R., Skelton, J. A., Kelsey, M. M., & Kelly, A. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab276 · Cited by 13
Lorcaserin Departs, Leaving More Questions than Answers
Kumar, R. B., & Ryan, D. H. (2020) · Obesity · doi:10.1002/oby.22789 · Cited by 13
Zomer, E., Zhou, J., Nelson, A. J., Sumithran, P., Nanayakkara, S., Ball, J., Kaye, D. M., Liew, D., Nicholls, S. J., Stub, D. A., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae063 · Cited by 12
Santos, G., Ikeda, J. M., Coffin, P. O., Walker, J. E., Matheson, T., McLaughlin, M. F., Jain, J. P., Vittinghoff, E., & Batki, S. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254724 · Cited by 12
“3 years of treatment and 6,000 who took placebo; all participants were overweight or obese, with cardiovascular disease or multiple cardiovascular disease risk factors (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients—Thrombolysis in Myocardial Infarction 61 [CAMELLIA-TIMI 61] clinic…”
Playdon, M. C., Hardikar, S. S., Karra, P., Hoobler, R., Ibele, A. R., Cook, K. L., Kumar, A., Ippolito, J. E., & Brown, J. C. (2023) · JNCI Monographs · doi:10.1093/jncimonographs/lgad003 · Cited by 14
“During the cardiovascular outcome study in 12000 participants, a potential signal of increased cancers and cancer-related mortality was identified (96).”
BackgroundStumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Tratamiento farmacológico de la obesidad para médicos de Atención Primaria
Rubio, M. Á., Fernández-García, J. M., Andújar, R. C., Altozano, C. S., & Carpi, J. J. U. (2019) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2019.04.005 · Cited by 19
An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity
Tchang, B. G., Abel, B., Zecca, C., Saunders, K. H., & Shukla, A. P. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1685496 · Cited by 12
“CVD [31] CKD [33] Prediabetes [32] T2DM [32]”
InfluentialLeventhal-Perek, S., Shani, M., & Schonmann, Y. (2023) · Family Practice · doi:10.1093/fampra/cmac141 · Cited by 11
Current perspectives on brain circuits involved in food addiction-like behaviors
Senol, E., & Mohammad, H. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-023-02732-4 · Cited by 11
Harrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 12
“The field has been further limited by the closure of the company making the weight-loss combination drug, bupropion/naltrexone, by the potential for an increased risk for cancer seen with lorcaserin, and by increased suicidal ideation with rimonabant [23, 28, 29].”
Self-citationTreating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Andrew, C. A., Saunders, K. H., Shukla, A. P., & Aronne, L. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561867 · Cited by 11
“This study supports the safety of using lorcaserin in patients with CVD [12].”
ResultNovel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
“lorcaserin is at least safe in this respect but disappointingly demonstrates no improvements to cardiovascular health [9].”
BackgroundRhus verniciflua leaf extract suppresses obesity in high-fat diet-induced obese mice
Suruga, K., Tomita, T., Kadokura, K., & Arai, T. (2019) · Food & Nutrition Research · doi:10.29219/fnr.v63.3601 · Cited by 12
A closer look at weight loss interventions in primary care: a systematic review and meta-analysis
Perreault, L., Kramer, E. S., Smith, P. C., Schmidt, D. W., & Argyropoulos, C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1204849 · Cited by 14
“Medications for weight loss are being more 68 extensively studied and demonstrating improved outcomes.(8-11) Bariatric surgery provides a 69 possible option to address weight and reverse potentially life-threatening conditions such as 70 heart disease and diabetes in both adolescents and adults.”
Background5-HT2C agonism as a neurotherapeutic for sarcopenia: preclinical proof of concept
Kerr, N. R., Dashtmian, A. R., Darvishi, F. B., Brennan, C. D., Ayyagari, S. N., Moore, P. J., Viteri, J. A., Wang, M., Rich, M. M., Clark, B. C., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01519-7 · Cited by 11
“While lorcaserin was previously approved by the FDA as a weight loss drug (under the name Belviq), its approval was voluntarily withdrawn in 2020 due to a slight increase in cancer incidence [65].”
Cardiovascular effects of antiobesity drugs: are the new medicines all the same?
Cataldi, M., Cignarelli, A., Giallauria, F., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. A. L. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0015-3 · Cited by 11
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Patel, S. M., Morrow, D. A., Bellavia, A., Berg, D. D., Bhatt, D. L., Jarolím, P., Leiter, L. A., McGuire, D. K., Raz, I., Steg, P. G., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3118 · Cited by 9
Self-citationEnhanced browning of adipose tissue by mirabegron-microspheres
Niu, Z., Hildebrand, S., Kappes, S., Ali, M. R., Vogel, M., Mikhael, M., Ran, D., Kožák, J., Wiedner, M., Richter, D. F., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.025 · Cited by 9
Serotonin neurons integrate GABA and dopamine inputs to regulate meal initiation
Conde, K., Wong, H., Fang, S., Li, Y., Yu, M., Deng, Y., Liu, Q., Fang, X., Wang, M., Shi, Y., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156099 · Cited by 10
Lorcaserin in obesity: minimal benefits and ill-defined harms
Onakpoya, I., & Aronson, J. K. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111128 · Cited by 9
Kiguti, L. R. D. A., Pacheco, T. L., Antunes, E., & Kempinas, W. D. G. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.02.027 · Cited by 9
Kapoor, E., Faubion, S. S., Hurt, R. T., Fischer, K. M., Schroeder, D. R., Fokken, S. C., & Croghan, I. T. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001599 · Cited by 10
“1%, respectively).(38) Before this study, there”
Ram, E., Klempfner, R., Peled, A., Kassif, Y., Sternik, L., Lavee, J., & Peled, Y. (2020) · Clinical Transplantation · doi:10.1111/ctr.14187 · Cited by 9
Zhang, L., Liu, Z., Liao, S., He, H., & Zhang, M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03160-7 · Cited by 11
Colognesi, M., Gabbia, D., Signor, A., Sarill, M., Centofanti, L., Rinaldi, A., Cascione, L., Nunziata, S., Banzato, M., Mattarei, A., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108080 · Cited by 8
Gündüz, M. K. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03261-z · Cited by 8
“Obesity has evolved into a public health issue, and combating it has become a global concern [4, 5].”
BackgroundLorcaserin: Worthy of Further Insights? Results from Recent Research
Mazza, M., Kotzalidis, G. D., Marano, G., Berardis, D. D., Martinotti, G., Romagnoli, E., Biondi‐Zoccai, G., Abbate, A., & Sani, G. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330124137 · Cited by 8
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Hypothalamic GPCR Signaling Pathways in Cardiometabolic Control
Deng, Y., Deng, G., Grobe, J. L., & Cui, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.691226 · Cited by 8
Serotonin is elevated in risk-genotype carriers of TCF7L2 - rs7903146
Leiherer, A., Muendlein, A., Saely, C. H., Fraunberger, P., & Drexel, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-49347-y · Cited by 7
Prevention of Diabetes Macrovascular Complications and Heart Failure
Sattar, N. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.004 · Cited by 7
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendra, K., Taha, A., Nadarajah, R., et al. (2025) · Heart · doi:10.1136/heartjnl-2025-326045 · Cited by 7
Natali, L. D., de Oliveira, L. G. M. S., Barbosa, I. C. D. Q., & Portilho, N. D. P. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.07.009 · Cited by 7
Pharmaceutical approaches to weight management: behavioural mechanisms of action
Roberts, C. A., Christiansen, P., & Halford, J. C. G. (2019) · Current Opinion in Physiology · doi:10.1016/j.cophys.2019.04.017 · Cited by 7
Kuo, H., Wang, K., Lee, Y., Lin, P., Liu, M., Lin, C., & Liu, L. Y. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13047 · Cited by 6
Safety and efficacy of pharmacologic weight loss in patients with cirrhosis
Fakhreddine, A. Y., Bagsic, S. R. S., Fujioka, K., & Frenette, C. T. (2020) · Obesity Science & Practice · doi:10.1002/osp4.469 · Cited by 6
“It's worth noting that since the design of this study, lorcaserin was voluntarily withdrawn from the market following an FDA request in February 2020 due to increased incidence of cancer in the CAMELLIA‐TIMI 61 study.(25) Phentermine use additionally may be limited given increasing prevalence of NAFLD with associated…”
MethodCurrent Options for the Pharmacotherapy of Obesity
Gouni‐Berthold, I., & Berthold, H. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190708192630 · Cited by 7
Pirlet, C., Poirier, P., Cieza, T., Piché, M., Biertho, L. D., Maes, F., Ruzsa, Z., & Bertrand, O. F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00428-8 · Cited by 6
Agreement Between Mega-Trials and Smaller Trials: A Systematic Review and Meta-Research Analysis
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32296 · Cited by 7
Reddy, G. S., Kamaraj, R., Hossain, K. A., Kumar, J. S., Thirupataiah, B., Medishetti, R., Sri, N. S., Misra, P., & Pal, M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105380 · Cited by 5
Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials
Linden, K., McQuillan, C., Brennan, P., & Menown, I. B. A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00962-1 · Cited by 5
Lee, C. J., Kim, M.-J., & An, S. J. (2019) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2019.19.4.171 · Cited by 5
Prevalence and Management of Adult Obesity in a Large U.S. Academic Health System
Lumsden, R. H., Pagidipati, N. J., Phelan, M., Chiswell, K., & Peterson, E. D. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.01.018 · Cited by 5
Jing, M., Wang, S., Li, D., Wang, Z., Li, Z., Lu, Y., Sun, T., Qiu, C., Chen, F., Yu, H., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.761966 · Cited by 5
Kulkarni, G., Murala, S., & Bollu, P. C. (2022) · Springer eBooks · doi:10.1007/978-3-031-07897-2_2 · Cited by 7
Has the bloom gone out of lorcaserin following the CAMELLIA-TIMI61 trial?
Mathai, M. L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1858795 · Cited by 5
Perreault, L., Suresh, K., Rodríguez, C., Dickinson, L. M., Willems, E., Smith, P. C., Williams, J., Gritz, R. M., & Holtrop, J. S. (2023) · The Annals of Family Medicine · doi:10.1370/afm.2966 · Cited by 7
Drug Induced Valvular Heart Disease
Cerón, C., Goyal, A., & Makaryus, A. N. (2019) · StatPearls · Cited by 4
Hurt, R. T., Croghan, I. T., Schroeder, D. R., Choi, D., Fischer, K. M., Fokken, S. C., & Ebbert, J. O. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.01.004 · Cited by 4
Skovgaard, D. C., Haahr, P., Lester, R., Clark, K., Paglialunga, S., Finer, N., Friedrichsen, M. H., Hjerpsted, J., & Engelmann, M. D. M. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2193 · Cited by 4
“…but not limited to arrhythmia) associated with early weight management medications (eg, sibutramine, 8,9 tesofensine, 10 fenfluramine, 11 lorcaserin 12 ) and the potential for an arrhythmogenic impact of rapid weight loss, 13 it is pertinent to study the effect of new weight management medications…”
Fujioka, K., Perdomo, C. A., & Malhotra, M. (2019) · Obesity Science & Practice · doi:10.1002/osp4.340 · Cited by 4
“The effect of lorcaserin on OSA will be prospectively evaluated in a phase 3 study evaluating the effect of long-term treatment with lorcaserin on the incidence of major adverse CV events in persons with obesity and overweight persons with CV disease or multiple CV risk factors (34).”
BackgroundSelf-citationLorcaserin — Elixir or Liability?
Ingelfinger, J. R., & Rosen, C. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1810855 · Cited by 4
Trials and Tribulations in Studying Kidney Outcomes With Intentional Weight Loss
Navaneethan, S. D. (2019) · Circulation · doi:10.1161/circulationaha.118.038677 · Cited by 5
Khattab, T., & Aljeesh, Y. I. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200466 · Cited by 3
“This study underscores obesity and overweight as significant risk factors for CVD, linked to comorbidities including HTN, dyslipidemia, type 2 DM, CAD, stroke, heart failure, and elevated mortality [46].”
Survodutide for the Treatment of Obesity
Platz, E., Kaplan, L. M., le Roux, C. W., Wharton, S., Burger, S., Hussain, S. A., Brueckmann, M., Startseva, E., Fey, C., Kosiborod, M., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102780 · Cited by 3
Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines
Platz, E., Peikert, A., Bozkurt, B., der Schueren, B. V., Butler, J., Lingvay, I., McGuire, D. K., Zannad, F. M., & Sattar, N. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.013 · Cited by 3
Self-citationLorcaserin: balancing efficacy with potential risks
Unamuno, X., & Frühbeck, G. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32460-7 · Cited by 3
Treatment of Delayed Ejaculation
Piche, K., Mann, U., & Patel, P. (2020) · Current Sexual Health Reports · doi:10.1007/s11930-020-00287-z · Cited by 4
Open-label pilot of lorcaserin (a serotonin 2C-receptor agonist) for cannabis use disorder
Brezing, C., Sibai, M., Choi, C. J., Mitra, S., Mariani, J. J., Naqvi, N. H., Mahony, A. L., Brooks, D., Pavlicová, M., & LEVIN, F. R. (2023) · Journal of Substance Use · doi:10.1080/14659891.2023.2202760 · Cited by 3
“(Bohula et al., 2018) Rimonabant, an endo-cannabinoid receptor antagonist, demonstrated unacceptably high rates of serious neuropsychiatric side effects, including suicidal ideation.”
Epidemiologie, Prävention und Therapie der Adipositas
Lautenbach, A., & Aberle, J. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0486-4 · Cited by 3
Gündüz, M. K. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065594 · Cited by 3
Prasad, S., Murphy, S. A., Morrow, D. A., Scirica, B. S., Sabatine, M. S., Berg, D. D., & Bellavia, A. (2025) · Annals of Epidemiology · doi:10.1016/j.annepidem.2025.10.012 · Cited by 3
Self-citationGarvey, W. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00018-8 · Cited by 2
Jang, Y., Park, W.-B., & Lee, M.-G. (2023) · Korean Journal of Sport Science · doi:10.24985/kjss.2023.34.1.1 · Cited by 3
Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
Moura, F. A., Bellavia, A., Berg, D. D., Melloni, G. E. M., Feinberg, M. W., Leiter, L. A., Bohula, E. A., Morrow, D. A., Scirica, B. A., Wiviott, S. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15798 · Cited by 2
Self-citationDistinct Hypothalamic and Brainstem Contributions to Lorcaserin Action
Zeltser, L. M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.016 · Cited by 2
Weight loss: Lifestyle interventions and pharmacotherapy
Poku, C. A., Tahsin, B., & Fogelfeld, L. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815290-4.00016-6 · Cited by 2
Team-based strategies to prevent heart failure
Taha, M. B., Patel, K. V., & Nasir, K. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000959 · Cited by 2
Kumar, J. S., Naimisha, R., Thirupataiah, B., Reddy, G. S., Bung, N., Roy, A., Bulusu, G., Mishra, A., Yadav, P. N., Misra, P., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106202 · Cited by 3
Defining Predictors of Weight Loss Response to Lorcaserin
Sideri, A., Dimino, C., Panigrahi, S. K., Mayer, L. S., Smiley, R. M., Körner, J., & Wardlaw, S. L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad139 · Cited by 3
How does lorcaserin facilitate weight loss and who will benefit?
Roberts, C. A., & Halford, J. C. G. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0109-y · Cited by 3
The sEROtonergic pathway: a hERO for the brain, a zERO for the valves?
Backer, T. L. M. D., & Timmermans, F. (2019) · Heart · doi:10.1136/heartjnl-2018-314551 · Cited by 2
Lorcaserin Safety in Overweight or Obese Patients
Coomes, E. A., Haghbayan, H., & Zipursky, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813971 · Cited by 2
Identification of genes associated with sudden cardiac death: a network- and pathway-based approach
Wei, J., Ni, X., Dai, Y., Chen, X., Ding, S., Bao, J., & Xing, L. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-361 · Cited by 1
“Moreover, PPARA is a famous gene in studying the mechanisms of overweight or obese patients, and is potentially one of the causes of SCD (62).”
BackgroundExemestane induces liver toxicity in zebrafish larvae by upregulating the p53 signaling pathway
Li, W., Zhou, X., Chen, W., Hu, W., Wang, Z., Xiao, Z., Yuan, W., Lian, J., Xiao, J., Cao, Z., et al. (2025) · Fish Physiology and Biochemistry · doi:10.1007/s10695-025-01588-7 · Cited by 1
Rustandi, T., Hayati, F., Nugroho, F., Amalia, S. P., Nastasya, R., & Mahal, A. (2025) · Frontiers in Natural Products · doi:10.3389/fntpr.2025.1694933 · Cited by 1
Kyle, M., Savastano, D. M., Sharpe, T. A., & Kelly, B. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100280 · Cited by 1
“This analysis concluded that over a mean of 4.7 years of observation, patients who received NB-ER did not have an increased risk of MACE compared with lorca-serin, for which neutral CV findings were reported in a CV outcomes trial [6,19].”
InfluentialBruno, J., Carruthers, D., & Alemán, J. O. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_8 · Cited by 1
Metadata
- Authors
- Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., Garcia-Castillo, A., Gupta, M., Leiter, L. A., Weissman, N. J., White, H. D., Patel, T., Francis, B., Miao, W., Perdomo, C., Dhadda, S., Bonaca, M. P., Ruff, C. T., Keech, A. C., Smith, S. R., Sabatine, M. S., & Scirica, B. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston (E.A.B., S.D.W., J.K., K.I., A.Q., M.P.B., C.T.R., M.S.S., B.M.S.); the Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas (D.K.M.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); the Department of Medicine, University of Minnesota, Minneapolis (C.L.F.); the Partners Clinical Research Centre, Nassau,...
- ORCID
- Bohula, Erin A.
- Wiviott, Stephen D.
- McGuire, Darren K.
- Inzucchi, Silvio E.
- Kuder, Julia
- Fanola, Christina L.
- Qamar, Arman
- Budaj, Andrzej
- Gupta, Milan
- Leiter, Lawrence A.
- White, Harvey D.
- Patel, Tushar
- Perdomo, Carlos
- Dhadda, Shobha
- Bonaca, Marc P.
- Ruff, Christian T.
- Keech, Anthony C.
- Smith, Steven R.
- Sabatine, Marc S.
- Scirica, Benjamin M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-09-20
- Volume
- 379
- Issue
- 12
- Pages
- 1107-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2888628330
- Cited by
- 265
- References
- 28
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 20 · 2023: 32 · 2022: 30 · 2021: 36 · 2020: 41 · 2019: 57 · 2018: 18
- FWCI
- 24.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eisai
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- lorcaserin, cardiovascular safety, obesity, overweight, weight loss, appetite suppressants, major adverse cardiovascular events, non-inferiority, heart failure, hypoglycemia, atherosclerotic cardiovascular disease, weight management, adverse events, serious adverse events, cardiovascular risk factors, coronary revascularization, myocardial infarction
- MeSH terms
- Aged, Aortic Valve Insufficiency, Benzazepines, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Pulmonary, Hypoglycemia, Male, Middle Aged, Obesity, Risk Factors, Weight Loss, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.